archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Product Pipeline Descriptions
    aiming to develop recombinant therapeutic proteins particularly monoclonal antibodies CSL324 G CSFR Recombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor receptor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases CSL346 VEGFB A humanised mAb that antagonises VEGF B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the treatment of type II diabetes or other conditions associated with aberrant lipid metabolism FXIIa Antagonist Research program investigating potential Anti FXIIa monoclonal antibody in HAE and Thrombosis Clinical Development Market Development Hizentra CIDP Global study assessing the use of Hizentra 20 subcutaneous immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy CIDP Fibrinogen Aortic EU Clinical studies testing the use of Fibrinogen concentrate as a quickly administered fast acting low volume medicine to microvascular bleeding to reduce the need for donated allogenic blood products Zemaira EU Alpha1 Proteinase Inhibitor in subjects with emphysema due to A1PI deficiency Berinet Subcutaneous A volume reduced lyophilized pasteurized nanofiltered C1 esterase inhibitor concentrate derived from human plasma suitable for the subcutaneous route of administration by self application New Product Development CSL689 rVIIa FP Recombinant coagulation factor VIIa with extended half life Phase I study initiated CSL654 rIX FP Recombinant coagulation factor IX with extended half life A Phase II III study in subjects with hemophilia B has commenced CSL627 rFVIII A unique single chain recombinant factor VIII rFVIII for treatment of Hemophilia A has entered Phase I clinical testing Partnered Vaccine Programs ISCOMATRIX Adjuvant Technology License and Option Agreements with several partners for multiple vaccine fields CSL362 IL 3R Janssen Recombinant Monoclonal Antibody against the IL 3 Receptor for the potential treatment of acute myeloid leukemia CAM3001 GM CSFR AZ Recombinant monoclonal antibody inhibiting GM CSF activity by targeting

    Original URL path: http://www.csl.com.au/research-development/product-pipeline/descriptions.htm (2014-01-05)
    Open archived version from archive


  • Access to Medicines
    one of the leading causes of disabilities in infants including deafness blindness cerebral palsy mental and physical disabilities seizures and even death The symptoms of CMV may not be immediately apparent at birth and even well beyond There is currently no proven therapeutic prevention for congenital CMV CSL is donating product made at its Swiss plant to the NIH for use in this trial as part of its commitment to addressing significant public health issues through collaborative research Helping to achieve equity of access to pandemic influenza vaccine In October 2009 CSL pledged 3 million doses of H1N1 influenza vaccine to the World Health Organization WHO to help protect those most at risk in developing countries in the South and Western Pacific and in South East Asia On announcing the pledge CSL s Chairman Elizabeth Alexander said Achieving equity of access to the H1N1 vaccine for developing countries remains a major global challenge As the only manufacturer of influenza vaccine in the Southern Hemisphere we have a unique role to play in not only helping to protect the health of Australians but those in our region CSL has since made a further gift of US 490 000 to the WHO to enable the purchase of syringes for our multi dose vials and to support the cold chain transport of our donated vaccine to recipient countries We have also helped support the deployment of pandemic vaccine donated by the Australian Government On 23 February 2010 we dispatched the very first shipment of Australian donated vaccine to Laos Since then further shipments have been made to Papua New Guinea Fiji Kirabati Tonga Vanuatu Maldives and Solomon Islands In April 2010 arrangements were being made for a shipment to Sri Lanka Improving Access to Life Saving Medicines On 17th April 2009 CSL Behring

    Original URL path: http://www.csl.com.au/corporate-responsibility/community/access-to-medicines.htm (2014-01-05)
    Open archived version from archive

  • Disaster Relief
    to the Queensland Premier s Disaster Relief Appeal and 100 000 to the Victorian Floods Appeal 2011 In addition CSL is supporting employee fundraising by matching dollar for dollar all contributions raised to support those affected by the floods As a major provider of essential medicines for Australians CSL is also working closely with local authorities Health Departments to ensure ongoing access to our therapies CSL s support of Haiti recovery efforts December 2010 In early 2010 on behalf of the CSL Group CSL Behring donated US 100 000 to support urgent relief efforts in neighbouring Haiti The donation to Habitat for Humanity will ensure necessary shelter and emergency provisions are provided to families affected by the devastating earthquake Additionally 5 000 syringes of Tetagam P and 1 600 5ml ampoules of Hepatitis B Immunoglobulin were donated to Direct Relief International DRI DRI is a charitable medical relief organization that assists communities affected by poverty disaster and civil unrest DRI will channel CSL s donation to the Hospital Albert Schweitzer in central Haiti Tetagam will be used in preventing and treating tetanus a serious public health problem in the developing world Tetanus is sometimes life threatening and is often associated with skin puncture wounds caused by rusted metal Hepatitis B Immune Globulin is used in treating exposure to the hepatitis B virus which can occur in a variety of ways If left untreated hepatitis B can become chronic threatening one s overall health and prognosis for recovery Becton Dickinson and Company BD supplied the needles and syringes to accompany CSL s product donation Furthermore in December 2010 CSL Behring donated to DRI critically needed medical supplies to assist cholera patients in Haiti The products will be used at Justinian University Hospital JUH in Cap Haitien JUH is the main public

    Original URL path: http://www.csl.com.au/corporate-responsibility/community/disaster-relief.htm (2014-01-05)
    Open archived version from archive

  • Fostering Science
    the Australian Institute of Policy and Science AIPS CSL is proud to sponsor the Florey Medal recognising an Australian biomedical researcher for significant achievements in biomedical science and human health advancement The health and economic well being of Australians is reliant upon the excellence of our practising scientists To this end CSL is committed to supporting the medical research community and recognising outstanding contribution to biomedical research by an Australian scientist CSL congratulates Professor Ruth Bishop the 2013 CSL Florey Medal winner for her life long work in saving the lives of young children worldwide commencing with the discovery of rotavirus a virus that up until its identification in 1973 put about 10 000 Australian children in hospital each year with acute gastroenteritis The Florey Medal was inaugurated in 1998 by the AIPS to celebrate the centenary of the birth of Sir Howard Florey Australia s Nobel Prize winner and discoverer of penicillin The Florey Medal is part of the Tall Poppy Campaign which aims to recognise and promote scientific and intellectual excellence in Australia In addition to the silver medal the 2013 award carries a cash prize of 50 000 2013 CSL Florey Medal Winner Professor Ruth Bishop Loading the video Past CSL Florey Medal winners include 2011 CSL Florey Medal Professor Graeme Clark for his life changing discovery Over the past thirty years hundreds of thousands of people have had their lives transformed by Graeme Clark s bionic ear 2009 CSL Florey Medal Professor John Hopwood for his life long work into the diagnosis and treatment of genetically inherited disorders that affect children Further details regarding the announcement of the award are available on the AIPS Website CSL fosters the next generation of medical researchers As an Australian company and global leader in developing medicines for rare and

    Original URL path: http://www.csl.com.au/corporate-responsibility/community/fostering-science.htm (2014-01-05)
    Open archived version from archive

  • Marketing Statement
    and details on your practice business eg size use of products as well as records of your dealings with CSL What will the information collected about me be used for The primary purpose for which CSL uses this information is to provide you with information about CSL s products and activities which may be of interest to you including the tailoring of marketing services to suit you the planning of meetings conferences and other events which may involve CSL and you and the generation of customer lists for CSL s market research In addition the information may also be used in connection with the supply of products or services to you to notify you of matters that CSL may be required by law to notify you of eg product recalls to administer and let you know about disease awareness management or similar programs organised by CSL and to monitor and review CSL s compliance with relevant regulations and codes of conduct Obviously to the extent that we do not collect information about you CSL will not be able to carry out these services and other purposes in relation to you or your practice business and you may not receive all of the benefits of information programs services or products that may be provided by CSL Will my information provided to anyone else CSL will maintain control and be responsible for the security of the personal information it holds As a general rule CSL will not provide it to any third parties except to regulatory bodies eg the TGA where CSL is under a legal obligation to provide the information to related companies of CSL for the same kinds of purposes as listed above to ensure continuity of service to another company if the supply of a product or service has been transferred to that company and to contractors engaged to provide services in connection with the purposes mentioned above such as mail out companies agencies engaged to organise conferences and database managers who maintain and update contact information and who may contact you independently to check that information or your contact preferences and if it is otherwise permitted or required by the Privacy Act or any other law How does CSL collect this information about me In most cases CSL collects information directly from you Where it is not practicable to collect information directly from you CSL may collect this information from members of your practice or business publicly available sources and third parties such as industry bodies professional associations direct mail companies Information will only be collected from third parties who satisfy CSL that in collecting the personal information they have complied with the Privacy Act and all other relevant laws What laws require CSL to collect personal information about me CSL may be required under state and territory poisons legislation to collect personal information about you when it supplies prescription drugs to you CSL may also be required under federal legislation to collect personal information about you to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1199979231933/content/1196562762133/content.htm (2014-01-05)
    Open archived version from archive

  • Search Results
    ar 2010 pdf CSL LIMITED OUR CORPORATE RESPONSIBILITY 2012 CSL LIMITED OUR CORPORATE RESPONSIBILITY 2012 Go to Contents Next page CSL Limited ABN 99 051 588 348 Our Corporate Responsibility 2012 Contents 3 1 Performance 12 3 2 Safety http www csl com au Responsibility 202012 FNL WEB 1 pdf CSL Limited Our Corporate Responsibility 2011 CSL Limited Our Corporate Responsibility 2011 Go to Contents Next page CSL Limited ABN 99 051 588 348 Our Corporate Responsibility 2011 Now ABLe to LeAd more NormAL LiveS http www csl com au docs 733 154 CSL CR 2011FNL pdf CSL Limited CSL Limited 2013 július Cégünk felelős üzleti gyakorlat szabályzata közzététel 07 2 6 Kereskedés CSL részvényekkel 08 2 7 Kereskedelmi http www csl com au docs 492 209 CSL CRBP13i HUN001 pdf Microsoft Word CSL ASX reporting App 4E 30 June 2013 Final CSL Limited ABN 99 051 588 348 ASX Full year information 30 June 2013 Lodged with the Directors Report Financial Report CSL Limited ABN 99 051 588 348 Appendix 4E http www csl com au 2030 20June 202013 20 compiled pdf Month 00 0000 CSL Limited ABN 99 051 588 348 ASX Full year information 30 June 2012 Lodged with the Directors Report Financial Report CSL Limited ABN 99 051 588 348 Appendix 4E http www csl com au L FY 2012 Financial Information pdf CSL Limited CSL Limited Juli 2013 Onze code voor verantwoorde bedrijfspraktijken Inhoud 1 2 3 4 2 5 Openheid van bestuur 07 2 6 Handel in CSL aandelen 08 2 7 Handelspraktijken 08 2 8 http www csl com au L CRBP13i BEL001 20FlemishDutch pdf CSL Limited CSL Limited Índice Julio 2013 Nuestro Código de Prácticas Comerciales Responsables 1 Página siguiente Página anterior Contents CSL Limited ABN 99 051 588 348 Nuestro http

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=10&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • Search Results
    7 Handelspraktiken 08 2 8 http www csl com au 877 CSL CRBP13i Deu001 20German pdf CSL Limited CSL Limited Innehåll juli 2013 Vår kodex för ansvarsfull affärspraxis 1 2 3 4 5 Contents CSL Limited ABN 99 051 588 348 Vår kodex för ansvarsfull affärspraxis juli http www csl com au 45 CSL CRBP13i SWE001 20Swedish pdf CSL Limited CSL Limited July 2013 Our Code of Responsible Business Practice Contents 1 2 3 4 5 Continuous disclosure 07 2 6 Trading in CSL shares 08 2 7 Trade practices 08 2 8 http www csl com au 49 CSL CRBP13i Eng001 20English pdf Microsoft Word CSL Group Financial Statements 30 June 2011 CSL Limited ABN 99 051 588 348 ASX Full year information 30 June 2011 Lodged with the Directors Report Financial Report CSL Limited ABN 99 051 588 348 Appendix 4E http www csl com au 20Financial 20Information 20v3 pdf CSL Limited CSL Limited Ιούλιος 2013 Ο Κώδικάς μας για Υπεύθυνη μετοχών της CSL 08 2 7 Πρακτικές http www csl com au 29 CSL CRBP13i GRC001 20Greece pdf CSL Limited CSL Limited Lipiec 2013r Nasz kodeks odpowiedzialnych praktyk biznesowych Spis treści 07 2 6 Obrót papierami wartościowymi CSL 08 2 7 Praktyki handlowe 08 2 8 Konflikty http www csl com au docs 800 118 CSL CRBP13i POL001 pdf CSL Limited CSL Limited Juillet 2013 Notre Code de Pratique Professionnelle Responsable Sommaire 1 continue 07 2 6 Opérations sur Titres CSL 08 2 7 Pratiques commerciales 08 2 8 http www csl com au docs 856 243 CSL CRBP13i FRA001 pdf CSL Limited CSL Limited Červenec 2013 Náš kodex odpovědného chování v rámci obchodní s cennými papíry společnosti CSL 08 2 7 Postupy pro obchodování 08 2 8 http www csl com au docs 895 1001 CSL

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=20&dropXSL=yes (2014-01-05)
    Open archived version from archive

  • Search Results
    pdf Sales revenue CSL Limited ABN 99 051 588 348 ASX Full year information 30 June 2008 Lodged with the Directors Report Financial Report CSL Limited ABN 99 051 588 348 Appendix 4E http www csl com au 2030 20June 202008 20compiled pdf Microsoft Word Cvr letter 06 07 results doc CSL Limited ABN 99 051 588 348 ASX Full year information 30 June 2007 Lodged with the Report including Directors Report CSL Limited ABN 99 051 588 348 Appendix 4E http www csl com au 734 116 ASXFullYearInformation pdf CSL LImItEd ShaREhOLdER REvIEw CSL LImItEd ShaREhOLdER REvIEw 2012 2013 Interim unfranked dividend of 50 per share Shareholder Review 2012 2013 CSL Limited ABN 99 051 588 348 Financial calendar 2014 12 http www csl com au docs 457 430 CSL SHR 2013 0 pdf CSL LIMITED CSL LIMITED SHAREHOLDER REVIEW 2011 2012 Financial calendar 2013 20 February Half year CSL Limited ABN 99 051 588 348 Shareholder Review 2011 2012 annual General MeetinG http www csl com au docs 520 256 csl shr 2012 0 pdf Annual Report Annual Report 2007 2008 CSL Limited CSL Limited ABN 99 051 588 348 Annual Report 2007 2008 Year in Review 1 Highlights 2 Financial Results 3 Year in Review Business Features 8 CSL http www csl com au docs 565 929 CSL AR 2008 pdf IVIG Demand in the US is Growing 1 CSL Group CSL Group CSL GROUP CSL GROUP 2 CSL Group CSL Group CSL s Record Year CSL s Record Year Strong Financial Performance Strong Financial Performance Revenues http www csl com au 864 645 AnalystPresentation2002 pdf CSL Ltd products provide treatment of serious medical conditions Global Home CSL Behring Global bioCSL All CSL Websites CSL Include All CSL Behring Country Sites Choose country Austria Belgium Luxembourg Brazil

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1255924054987/page/1255924054283/SearchResults.htm?query=csl&pr=CSLsites&prox=page&rorder=500&rprox=500&rdfreq=500&rwfreq=500&rlead=500&rdepth=0&sufs=0&order=r&cq=2&jump=30&dropXSL=yes (2014-01-05)
    Open archived version from archive